Tenaya Therapeutics (TNYA) Other Non-Current Assets (2020 - 2026)
Tenaya Therapeutics (TNYA) posted quarterly Other Non-Current Assets of $3.8 million for Q1 2026, down 21.36% year-over-year from $4.8 million in Q1 2025, and down 10.86% quarter-over-quarter from $4.2 million in Q4 2025.
Tenaya Therapeutics (TNYA) Other Non-Current Assets (2020 - 2026) Analysis & Trends
Tenaya Therapeutics' Other Non-Current Assets history runs 7 years deep, the most recent figure standing at $3.8 million for Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 21.36% year-over-year to $3.8 million; the TTM figure through Mar 2026 stood at $3.8 million (down 21.36% YoY), while the FY2025 annual figure was $4.2 million, down 11.85% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $3.8 million, down from $4.2 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $5.7 million in Q3 2023, with the low at $399000.0 in Q1 2022.
- The 5-year median for Other Non-Current Assets is $4.8 million (2022), against an average of $4.5 million.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Assets slipped 27.06% in 2022, then jumped 1060.4% in 2023.
- Tenaya Therapeutics' Other Non-Current Assets stood at $4.8 million in 2022, then advanced by 18.44% to $5.7 million in 2023, then fell by 15.15% to $4.8 million in 2024, then declined by 11.85% to $4.2 million in 2025, then retreated by 10.86% to $3.8 million in 2026.
- Business Quant data shows TNYA's Other Non-Current Assets at $3.8 million in Q1 2026, $4.2 million in Q4 2025, and $4.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Tenaya Therapeutics | 151.50 Mn | 151.50 Mn | - | 2.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.07 Mn |
| Mar 31, 2026 | 3.79 Mn |
| Dec 31, 2025 | 4.25 Mn |
| Sep 30, 2025 | 4.24 Mn |
| Jun 30, 2025 | 4.31 Mn |
| Mar 31, 2025 | 4.81 Mn |
| Dec 31, 2024 | 4.82 Mn |
| Sep 30, 2024 | 4.87 Mn |
| Jun 30, 2024 | 5.06 Mn |
| Mar 31, 2024 | 5.63 Mn |
| Dec 31, 2023 | 5.68 Mn |
| Sep 30, 2023 | 5.73 Mn |
| Jun 30, 2023 | 5.54 Mn |
| Mar 31, 2023 | 4.63 Mn |
| Dec 31, 2022 | 4.79 Mn |
| Sep 30, 2022 | 4.65 Mn |
| Jun 30, 2022 | 3.71 Mn |
| Mar 31, 2022 | 399,000.00 |
| Dec 31, 2021 | 4.13 Mn |
| Sep 30, 2021 | 3.53 Mn |